Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.
Last trade$15.64
Day change+$0.42 (+2.76%)
Day range$15.16 – $16.30
Volume276,276
Market cap$482M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$482.29M
Price / earnings
—
Price / book
-15.54×
Price / sales
5.7×
EV / sales
6.11×
EV / EBITDA
-19.76×
Profitability
Earnings per share
-$1.14
Return on assets
-77.18%
Return on equity
116.37%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-1.47×
Current ratio
1.2×
Quick ratio
0.99×
Cash ratio
0.46×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$20.15M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for RCEL, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$26.11M
$21.7M
$19.25M
$17.62M
$17.06M
$18.42M
$18.51M
$18.41M
Cost of revenue
$4.17M
$3.94M
$3.52M
$3.3M
$3.19M
$3.47M
$2.83M
$2.28M
Gross profit
$21.94M
$17.77M
$15.73M
$14.31M
$13.88M
$14.95M
$15.68M
$16.13M
Selling, general and administrative
$19.87M
$19.54M
$18.9M
$19.03M
$19.28M
$20.98M
$21.22M
$21.23M
Research and development
$4.7M
$5.08M
$5.63M
$5.69M
$3.75M
$5.12M
$6.28M
$4.85M
Total operating expenses
$24.57M
$24.62M
$24.53M
$24.72M
$23.03M
$26.1M
$27.51M
$26.08M
Operating income
-$2.63M
-$6.86M
-$8.8M
-$10.41M
-$9.15M
-$11.15M
-$11.83M
-$9.96M
Interest expense
-$1.48M
-$1.46M
-$1.42M
-$1.25M
-$1.27M
-$1.25M
-$1.23M
-$1.3M
Income before taxes
-$6.16M
-$7.63M
-$10.62M
-$11.64M
-$13.17M
-$9.92M
-$13.85M
-$11.57M
Income taxes
$65K
$33K
-$11K
-$17K
$15K
$4K
$8K
$19K
Net income
-$6.22M
-$7.66M
-$10.61M
-$11.62M
-$13.19M
-$9.92M
-$13.86M
-$11.59M
Net income attributable to common shareholders
-$6.22M
-$7.66M
-$10.61M
-$11.62M
-$13.19M
-$9.92M
-$13.86M
-$11.59M
EBITDA
-$2.04M
-$6.25M
-$8.18M
-$9.71M
-$8.58M
-$10.6M
-$11.31M
-$9.55M
Basic earnings per share
-$0.20
-$0.25
-$0.35
-$0.38
-$0.46
-$0.38
-$0.53
-$0.44
Diluted earnings per share
-$0.20
-$0.25
-$0.35
-$0.38
-$0.46
-$0.38
-$0.53
-$0.44
Recent news
Company coverage with links to the original publishers.
Avita Medical Inc. (RCEL) received an upgrade to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The upgrade reflects improving business fundamentals and positions the stock in the top 20% of Zacks-covered stocks, suggesting potential for near-term price appreciation driven by institutional investor buying pressure.
AVITA Medical announced strong third quarter 2026 results with 53% year-over-year revenue growth and raised its full year 2026 revenue guidance. The company also announced that the Centers for Medicare & Medicaid Services finalized national physician payment values and simplified billing codes for RECELL procedures effective 2027. An investor webinar is scheduled for November 11, 2026.
AVITA Medical announced its participation at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11-13, 2026. CEO Cary Vance will speak on August 12 at 8:00 a.m. ET, with a live webcast available on the company's investor relations website.
The global scar treatment market is projected to grow from USD 26.60 billion in 2025 to USD 56.30 billion by 2033, with a CAGR of 9.91%. Growth is driven by increasing awareness of advanced cosmetic and reconstructive procedures, rising prevalence of acne, surgical, and traumatic scars, and technological advancements in minimally invasive treatments. The U.S. market alone is expected to reach USD 17.69 billion by 2033.
AVITA Medical presented 19 scientific abstracts at the 2026 Boswick Burn & Wound Symposium, including the first surgeon-reported integrated use of its three technologies (RECELL, PermeaDerm, and Cohealyx) in patient cases. New clinical and histological data demonstrated that RECELL use was associated with smaller donor sites, faster healing times, improved pain and appearance outcomes, and more favorable health economics. Real-world studies showed RECELL reduced hospital stays by up to 36% in deep partial-thickness burns and nearly 16 days shorter stays in elderly burn patients.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.